Human Rotavirus Vaccine Companies

Latest Human Rotavirus Vaccine Companies Update

Nov 2023: Despite all its benefits, iNCOVACC entered the COVID-19 vaccine market later than its competitors, which limits the potential for financial success for Bharat Biotech. Bharat Biotech's nasal vaccination seeks to generate income from the home market, given that 98% of Indians have already received at least one dosage and 92% have received two doses of other vaccines.

Feb 2023: The nasal vaccine iNCOVACC, recently introduced by Bharat Biotech and hailed as a game-changer in stopping the spread of the coronavirus, can now be produced in quantities exceeding 10 million. The nasal vaccine from Bharat Biotech is the first intranasal vaccination to be approved globally for use as a booster and primary defense against COVID-19. Additionally, this vaccine can be swiftly altered to counteract newly developing, concerning variations. With all its benefits, iNCOVACC is a latecomer to the COVID-19 vaccine market, limiting its potential as a profitable economic venture for Bharat Biotech. When 92% of Indians have taken both doses and 98% of the population has already received one dosage of other vaccines, Bharat Biotech’s nasal vaccine is aiming to garner revenues from the domestic market.List of Human Rotavirus Vaccine Key companies in the market

• Bharat Biotech


• Serum Institute of India Pvt. Ltd.


• GlaxoSmithKline plc.


• Merck & Co., Inc.


• BIOVIRx Inc.


• Sanofi


• Lanzhou Institute of Biologicals Products Co., Ltd